Эффективность деносумаба при метастазах рака молочной железы в костях

Семенов Николай Николаевич · Вестник РОНЦ им. Н. Н. Блохина РАМН · 2011

This study compared efficacy of subcutaneous denosumab, 120 mcg, vs. intravenous zoledronic acid, 4 mg, every 4 weeks for 120 weeks in 34 patients with bone metastasis from breast cancer. Study end points were time to skeletal-related event (defined as pathological fracture, radiotherapy to bones by any reason, hypercalcemia), number of patients with skeletal-related events, frequency of skeletal-related events and changes in pain. Patients in the denosumab group demonstrated a longer time to skeletal-related event (809 vs. 754 days, p = 0.31). The number of patients with skeletal-related events in the denosumab group was 11.8% vs. 29.4% in the zoledronic acid group (p = 0.32). Frequency of skeletal-related events was 0.16 vs. 0.65 events per patient per year (p = 0.13). Pain reduced by month 9 by 62 and 42%, respectively. Long-term denosumab therapy proved highly efficient in patients with bone metastasis from breast cancer.

Cited by 0 works.

Authors